Novartis receives FDA approval for LESCOL XL 80 mg

New Formulation Provides Effective Treatment for Patients with Cholesterol, Triglyceride and other Lipid Disorders

EAST HANOVER, New Jersey - Novartis Pharmaceuticals Corporation today announced approval by the U.S. Food and Drug Administration for LESCOL XL (fluvastatin sodium) 80 mg, an extended-release tablet formulation of fluvastatin, a therapy that provides effective management of all major lipid parameters for patients with a variety of lipid disorders that place them at risk for heart disease. Phase III clinical trials demonstrate that LESCOL XL 80 mg produced up to 38 percent median decrease in low-density lipoprotein cholesterol (LDL-C) in patients with dyslipidemia, and a 25 percent median decrease in triglycerides (TG) and a 13 percent mean increase in high-density lipoprotein cholesterol (HDL-C) in patients with primary mixed dyslipidemia (Fredrickson Type IIb), as compared with LESCOL (fluvastatin sodium) 40 mg therapy.

"Physicians can use LESCOL XL as a starting dose to help patients effectively manage all major lipid parameters," said Paulo Costa, president and chief executive officer, Novartis Pharmaceuticals Corporation. "Phase III data demonstrate that this new formulation has the potential to bring the majority of patients who require statin therapy to their treatment goals."

For patients who have lipid disorders that place them at risk for heart disease, more than 90 percent can meet their treatment goals, as defined by the clinical application of the National Cholesterol Education Program (NCEP), by achieving a reduction of less than 30 percent in their LDL-C levels, according to empirical data from the National Health and Nutrition Examination Survey (NHANES III). The National Heart, Lung, and Blood Institute created the NCEP to contribute to reducing illness and death from coronary heart disease in the United States by reducing the percent of Americans with high blood cholesterol.


Contact: Anna Frable
Porter Novelli

Page: 1 2 3

Related medicine news :

1. Novartis announces collaboration with Bayer for EMSELEX
2. Dr. Judah Folkman honored with American Heart Association/Novartis award
3. Drs. Gerald DiBona and John Hall receive American Heart Association/Novartis award
4. Novartis receives FDA approval for Starlix, a new treatment for type 2 diabetes
5. UIC professor receives international humanitarian award
6. Mailman School of Public Health receives Manhattan Tobacco Cessation Center grant
7. Epidemiologist Trichopoulos receives $5.8 million Department of Defense Innovator Award
8. GlaxoSmithKline receives unanimous favorable recommendation by FDA Advisory Committee for Boostrix
9. NYU Child Study Center receives grant from the American Red Cross September 11 recovery program
10. Northwestern Memorial Hospital receives $10 million commitment to support preeminent heart program
11. American Academy of Neurology program receives Grassroots Award

Post Your Comments:

(Date:8/14/2019)... ... ... Teguar Corporation has claimed the #3719 position on the Inc. 5000 list ... mark of success for some of Americas top companies and has famously been occupied ... 2016 and 2017. This year, Teguar secured a spot on the list for a ...
(Date:8/14/2019)... ... 15, 2019 , ... R3 Stem Cell announced this week ... International is offering regenerative procedures with mesenchymal stem cells performed by highly experienced ... $2950, which includes a complete IV therapy or two joint injections. Patients receive ...
(Date:8/14/2019)... ... August 13, 2019 , ... In a recent Trivedi Effect workshop, Master ... your belief systems. , “Doubt can obliterate your old beliefs,” said Master Dahryn. “Doubt ... them to expand your understanding and your awareness. Trust that the Divine has put ...
(Date:8/14/2019)... ... August 14, 2019 , ... Today, consumers are taking ... drinks significantly impacts their physical body, emotions and energy levels. The trick is finding ... long run. , That’s why founder Chris Harper created Chase – ...
(Date:8/12/2019)... (PRWEB) , ... August 12, 2019 , ... Parents craving ... not only nourish their families but also help feed children in need. IsaKids® Super ... Celebration 2019 event in Nashville, Tennessee. The global health and wellness company also debuted ...
Breaking Medicine News(10 mins):
(Date:8/16/2019)... (PRWEB) , ... August 16, 2019 , ... ... Road in Gainesville GA, 30501, is a comprehensive family dental practice that serves ... within general dentistry, cosmetic dentistry , endodontics and restorative dental care. The ...
(Date:8/16/2019)... , ... August 16, 2019 , ... ... on its annual Inc. 5000 list, the most prestigious ranking of the nation’s ... companies within the American economy’s most dynamic segment—its independent small businesses. Microsoft, Dell, ...
(Date:8/16/2019)... ... August 16, 2019 , ... OCT Clinical Trials ... has successfully completed enrollment of 690 patients for a phase III efficacy study ... randomized, double-blind, placebo-controlled, home use, parallel group clinical trial of MED2002, which is ...
Breaking Medicine Technology:
Cached News: